Compare Natera Inc. Common Stock (NTRA) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs NEOS S&P 500 High Income ETF — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while NEOS S&P 500 High Income ETF trades at $53.58 (market cap $12.59B). The key difference: Natera Inc. Common Stock is far larger — about 4.5× NEOS S&P 500 High Income ETF's market cap, and NEOS S&P 500 High Income ETF is more actively traded (3,517,447 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and NEOS S&P 500 High Income ETF for 59 Days on average.
| NTRA | SPYI | |
|---|---|---|
Market Cap | $57.03B | $12.59B |
Volume | 1,131,157 | 3,517,447 |
Sector | Health | Income / Options Overlay |
52-Week High | $425.64 | $54.42 |
52-Week Low | $179.42 | $47.98 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SPYI trades at $54.11, showing minimal daily movement with a 0.02% gain. The ETF maintains a bullish technical outlook with strong moving average signals, though oscillators indicate neutral momentum. Recent news highlights SPYI's role in income-focused portfolios, with coverage discussing both its high distribution yields and the trade-offs between income generation and principal preservation in covered call strategies.
The outlook for SPYI reflects its niche as a high-income ETF using covered calls on the S&P 500. While the strategy provides substantial monthly distributions, investors face risks of capital erosion during strong bull markets due to capped upside. Current sentiment is mixed, balancing income appeal against long-term growth limitations in rising equity environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
